Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon a alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Bleumer I, Oosterwijk E, De Mulder P et al. Immunotherapy for renal cell carcinoma. Eur. Urol.44(1), 65–75 (2003).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol.159(4), 1163–1167 (1998).
   PubMed Web of Science ®Google Scholar
• Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J. Urol.173(6), 1889–1892 (2005).
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Urol.19(6), 1649–1657 (2001).
   Google Scholar
• Kattan MW, Reuter V, Motzer RJ et al. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol.166(1), 63–67 (2001).
   PubMed Web of Science ®Google Scholar
• Cindolo L, de la Taille A, Messina G et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int.92(9), 901–905 (2003).
   PubMed Web of Science ®Google Scholar
• Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol.21(16), 3133–3140 (2003).
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- and interferon-α2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer92(5), 843–846 (2005).
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Wilding G et al. Phase III study of interferon α-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol.21(7), 1214–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Hong SK, Kwak C, Lee SE. Adjuvant interleukin-2, interferon-α, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma. Urology66(3), 518–522 (2005).
   PubMedGoogle Scholar
• Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet363(9409), 594–599 (2004).
   PubMed Web of Science ®Google Scholar
• Margulis V, Matin SF, Tannir N et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology73(2), 337–341 (2009).
   PubMedGoogle Scholar
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res.11(10), 3714–3721 (2005).
   PubMed Web of Science ®Google Scholar
• Howdieshell TR, Callaway D, Webb WL et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J. Surg. Res.96(2), 173–182 (2001).
   PubMed Web of Science ®Google Scholar
• Roman CD, Choy H, Nanney L et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J. Surg. Res.105(1), 43–47 (2002).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21(1), 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol.19(3), 843–850 (2001).
   PubMed Web of Science ®Google Scholar
• Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol.180(1), 94–98 (2008).
   PubMed Web of Science ®Google Scholar
• Amin C, Wallen E, Pruthi RS et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology72(4), 864–868 (2008)
   PubMed Web of Science ®Google Scholar
• Kesmodel SB, Ellis LM, Lin E et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J. Clin. Oncol.26(32), 5254–5260 (2008).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J. Clin. Oncol.23(22), 4853–4855 (2005).
   PubMed Web of Science ®Google Scholar
• Gruenberger T, Gruenberger B, Scheithauer W. Neoadjuvant therapy with bevacizumab. J. Clin. Oncol.24(16), 2592–2594 (2006).
   PubMedGoogle Scholar
• Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol.171(3), 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin. Cancer Res.13(2 Pt 2), 727–732 (2007).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin. Cancer Res.13(2 Pt 2), 693–696 (2007).
   Google Scholar
• Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer113(7), 1552–1558 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Motzer RJ, Michaelson MD et al. Sunitinib therapy for patients with metastatic renal cell carcinoma: updated results of two Phase II trials and prognostic factor analysis for survival. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 5095).
   Google Scholar
• Feldman AL, Alexander HR, Yang JC et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer95(8), 1637–1643 (2002).
   PubMedGoogle Scholar
• Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol.177(6), 1978–1984 (2007).
   PubMed Web of Science ®Google Scholar
• Klatte T, Bohm M, Nelius T, Filleur S, Reiher F, Allhoff EP. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int.100(1), 209–214 (2007).
   PubMedGoogle Scholar
• McColl BK, Baldwin ME, Roufail S et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med.198(6), 863–868 (2003).
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Figlin RA, Atkins MB et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer107(10), 2375–2383 (2006).
   PubMed Web of Science ®Google Scholar
• Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr. Opin. Urol.18(5), 474–480 (2008).
   PubMed Web of Science ®Google Scholar
• Barney JD, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J. Urol.42, 269–276 (1939).
   Google Scholar
• Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: resection of solitary and multiple metastases. Ann. Thorac. Surg.54(1), 33–38 (1992).
   PubMed Web of Science ®Google Scholar
• Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol.16(6), 2261–2266 (1998).
   PubMed Web of Science ®Google Scholar
• Sherry RM, Pass HI, Rosenberg SA, Yang JC. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer69(7), 1850–1855 (1992).
   PubMed Web of Science ®Google Scholar
• Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch. Surg.127(11), 1343–1349 (1992).
   PubMedGoogle Scholar
• Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol.117(3), 272–275 (1977).
   PubMed Web of Science ®Google Scholar
• Russo P, Synder M, Vickers A, Kondagunta V, Motzer R. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. Scientific World Journal19(7), 768–778 (2007).
   Google Scholar
• Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol.158(5), 1675–1678 (1997).
   PubMed Web of Science ®Google Scholar
• Han KR, Pantuck AJ, Bui MH et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology61(2), 314–319 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-a as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol.154(1), 32–34 (1995).
   PubMed Web of Science ®Google Scholar
• Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur. Urol.54(3), 489–492 (2008).
   PubMed Web of Science ®Google Scholar
• Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J. Urol.180(3), 873–878 (2008).
   PubMed Web of Science ®Google Scholar